Independent
Tenure on this board
5.7 yrs
3 nominees · 2 ballot items.
Elect three Class III directors (Gregory R. Reyes, Tamara A. Favorito, Gregory D. Gorgas) and approve an amendment to the Articles to increase authorized common stock from 166,666,667 to 500,000,000.
Elect three (3) Class III director nominees — Gregory R. Reyes, M.D., Ph.D., Tamara A. Favorito and Gregory D. Gorgas — to serve until the 2029 Annual Meeting.
Approve amendment to the Articles of Incorporation to increase the number of authorized shares of common stock from 166,666,667 to 500,000,000.
This management proposal asks shareholders to approve an amendment to the company’s Articles of Incorporation to increase authorized common shares from 166,666,667 to 500,000,000, effectively creating a large pool of additional shares that the Board may issue without further shareholder approval. Management and the Board present the change as a tool to provide strategic and financial flexibility—to facilitate future public or private financings, support collaborations or M&A, enable equity incentives for recruitment and retention, and to allow opportunistic capital-raising without delay. The filing quantifies currently issued and reserved shares (2,848,540 issued and outstanding as of May 22, 2026, with significant reservations for warrants and option awards) to show that the existing authorized ceiling could constrain near-term financing or equity compensation needs. The Board also discloses that it currently has no definitive agreements to issue the new shares but references prior financing arrangements (an equity line and an ATM) and ongoing efforts to identify funding, framing the amendment as preemptive. While the Board emphasizes benefits, it also acknowledges potential anti-takeover implications and explicitly notes that future issuances could dilute existing holders’ voting power, EPS and book value; this disclosure signals a recognition of the primary shareholder downside risk. The proposal is classified as routine for broker voting purposes, which increases the likelihood that uninstructed shares held by brokers will be voted in favor. The Board’s unanimous recommendation underscores management’s view that the timing and magnitude of the increase are important to preserve optionality amid market volatility and limited current liquidity. For a sophisticated evaluation, the key trade-off is between managerial flexibility to execute financings and compensate employees versus the dilutionary and governance risks from a large overhang of authorized-but-unissued shares; investors should weigh the company’s capital needs, recent financing history, insider ownership/reservations, and any anti-takeover concerns when assessing the proposal.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC | 1.41% | 64,907 | $73K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 0.29% | 13,524 | $15K |
| 3 | StoneX Group Inc. | 0.27% | 12,400 | $15K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 0.22% | 10,129 | $11K |
| 5 | Tower Research Capital LLC (TRC | 0.18% | 8,435 | $9K |
| 6 | VANGUARD FIDUCIARY TRUST CO | 0.07% | 3,139 | $4K |
| 7 | UBS Group AG | 0.06% | 2,804 | $3K |
| 8 | JANE STREET GROUP, LLC | 0.03% | 1,434 | $2K |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 0.01% | 340 | $380 |
| 10 | TD Waterhouse Canada Inc. | 0.00% | 2 | $2 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.